Related Experiment Videos
Hematological malignancies and the bone (myeloma excluded)
1Rheumatology Department, Bicêtre Teaching Hospital, Le Kremlin-Bicêtre, Paris, France.
Joint Bone Spine
|August 30, 2000
Summary
Bone lesions in lymphomas are rare but indicate disease progression, impacting prognosis. Treatment for these hematologic malignancies involves systemic therapy, with local treatments for primary bone lymphomas.
Area of Science:
- Hematology
- Oncology
- Bone Biology
Background:
- Bone involvement is uncommon in lymphomas, except in adult T-cell leukemia/lymphoma (ATLL) linked to HTLV-I.
- Lytic bone lesions, typically in long bone metaphyses or the axial skeleton, signify disease progression and poorer prognosis.
- Bone lesions can also manifest in other lymphoproliferative and myeloproliferative disorders, potentially indicating a more aggressive disease state.
Purpose of the Study:
- To review the characteristics, prognosis, and treatment of bone involvement in hematologic malignancies.
- To explore the underlying mechanisms of bone lesions in these conditions.
Main Methods:
- Literature review of bone involvement in lymphomas and other hematologic malignancies.
- Analysis of disease characteristics, treatment strategies, and prognostic factors.
Main Results:
- Bone lesions in lymphomas are associated with advanced disease and depend on histologic type and stage.
- Treatment for systemic disease with bone lesions mirrors systemic therapy; primary bone lymphomas require local treatment (radiation/surgery) plus adjuvant chemotherapy.
- Hypercalcemia can be managed with glucocorticoids and bisphosphonates.
Conclusions:
- Bone lesions in hematologic malignancies, excluding myeloma and ATLL, have poorly understood mechanisms.
- Increased expression of RANK/RANKL is a potential pathway involved in bone resorption in these conditions.